(Q33351415)

26 July 2017

title

Approaches to optimal dosing of hexamethylene bisacetamide (English)

1 reference

26 July 2017

B. A. Conley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

M. J. Egorin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

V. Sinibaldi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

G. Sewack

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

C. Kloc

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

L. Roberts

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

E. G. Zuhowski

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

A. Forrest

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

D. A. Van Echo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1333894

14 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1333894

14 September 2022

publication date

1 January 1992

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

31

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

37-45

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00695992

26 July 2017

exact match

0 references

cites work

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

1 reference

12 December 2020

Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study

1 reference

12 December 2020

Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide

1 reference

12 December 2020

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

1 reference

12 December 2020

Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide

1 reference

12 December 2020

Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.

1 reference

12 December 2020

A program package for simulation and parameter estimation in pharmacokinetic systems

1 reference

12 December 2020

Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line

1 reference

12 December 2020

Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).

1 reference

12 December 2020

Phase I study of N-methylformamide in patients with advanced cancer

1 reference

12 December 2020

Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals

1 reference

12 December 2020

A new group of potent inducers of differentiation in murine erythroleukemia cells

1 reference

12 December 2020

Hexamethylene bisacetamide induces morphologic changes and increased synthesis of procollagen in cell line from glioblastoma multiforme

1 reference

12 December 2020

Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.

1 reference

12 December 2020

Induction of differentiation in mouse neuroblastoma cells by hexamethylene bisacetamide

1 reference

12 December 2020

Phase I trial of N-methylformamide (NMF, NSC 3051).

1 reference

12 December 2020

Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans

1 reference

12 December 2020

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

1 reference

12 December 2020

Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells

1 reference

12 December 2020

Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60.

1 reference

12 December 2020

Regression models in clinical studies: determining relationships between predictors and response

1 reference

12 December 2020

Neurologic, neuropathologic, and neurochemical effects of prolonged administration of phenylisopropylhydrazine (JB 516), phenylisobutylhydrazine (JB 835), and other monoamine oxidase inhibitors

1 reference

12 December 2020

Induction of transformed cells to terminal differentiation and the modulation of gene expression

1 reference

12 December 2020

Distribution, elimination, metabolism and bioavailability of hexamethylenebisacetamide in rats

1 reference

12 December 2020

Studies on the mechanism of action of hexamethylene bisacetamide, a potent inducer of erythroleukemic differentiation

1 reference

12 December 2020

The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.

1 reference

12 December 2020

Polar solvents: a novel class of antineoplastic agents

1 reference

12 December 2020

Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer

1 reference

12 December 2020

Heterogeneous responses of human colon carcinomas to hexamethylene bisacetamide

1 reference

12 December 2020

DMSO and retinoic acid induce HL-60 differentiation by different but converging pathways.

1 reference

12 December 2020

New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants.

1 reference

12 December 2020

Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent

1 reference

12 December 2020

Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00695992

1 reference

Dimensions Publication ID

26 July 2017

1007126994

0 references

1 reference